menu
    • menu

    Company profile for PAQ Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PAQ’s global team is pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s initial focus is on a genetic neurodegenerative disorder with no current...
    PAQ’s global team is pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s initial focus is on a genetic neurodegenerative disorder with no current treatment options for patients. PAQ plans to expand the ATTEC platform to target additional disease-causing protein and non-protein targets.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PAQ TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    625 Mass Ave. Office 02-146 Cambridge, MA, 02139
    Telephone
    Telephone
    540.958.1011
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.paqtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/paq-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PAQ Therapeutics Raises $77M, Doses First in PT0511 Phase 1
    PAQ Therapeutics Raises $77M, Doses First in PT0511 Phase 1

    22 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/paq-therapeutics-announces-series-b-extension-bringing-total-series-b-financing-to-77-million-first-patient-dosed-in-phase-1-trial-of-pt0511-a-pan-kras-degrader-302666808.html

    PR NEWSWIRE
    22 Jan 2026
    Share Share
    PAQ Therapeutics Raises $39M in Series B, Starts Phase 1 Trial
    PAQ Therapeutics Raises $39M in Series B, Starts Phase 1 Trial

    07 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/paq-therapeutics-announces-39-million-series-b-financing-and-initiates-phase-1-trial-to-advance-novel-approach-addressing-kras-driven-cancers-with-high-unmet-need-302447786.html

    PR NEWSWIRE
    07 May 2025
    Share Share
    PAQ Therapeutics Collaborate with Insilico Medicine to Develop Novel Therapies
    PAQ Therapeutics Collaborate with Insilico Medicine to Develop Novel Therapies

    09 Sep 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/paq-therapeutics-announces-collaboration-with-insilico-medicine-to-develop-novel-therapies-through-autophagy-dependent-degradation/?s=71

    BIOSPACE
    09 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search